Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Breast Cancer | Research

Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery

Authors: Raymond Javan Chan, Bruce Cooper, Louisa Gordon, Nicolas Hart, Chia Jie Tan, Bogda Koczwara, Kord M. Kober, Alexandre Chan, Yvette P. Conley, Steven M. Paul, Christine Miaskowski

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Purpose

To identify subgroups of female breast cancer patients with distinct self-reported employment interference (EI) profiles and determine which demographic, clinical, and symptom characteristics, and quality of life outcomes were associated with subgroup membership.

Methods

Women with breast cancer (n = 385) were assessed for changes in EI over ten times, from prior to, through 12 months after breast cancer surgery. Latent profile analysis (LPA) was used to identify subgroups of patients with distinct EI profiles.

Results

Three distinct EI profiles (i.e., None – 26.2% (n = 101), Low – 42.6% (n = 164), High – 31.2% (n = 120)) were identified. Compared to the None and Low groups, patients in the High group were more likely to be younger. Higher proportions in the High group were non-White, pre-menopausal prior to surgery, had more advanced stage disease, had received an axillary lymph node dissection, had received neoadjuvant chemotherapy, had received adjuvant chemotherapy, and had a re-excision or mastectomy on the affected breast within 6 months after surgery. In addition, these patients had lower quality of life scores. Compared to the None group, the High group had higher levels of trait and state anxiety, depressive symptoms, fatigue and sleep disturbance and lower levels of cognitive function.

Conclusions

This study provides new knowledge regarding EI profiles among women in the year following breast cancer surgery. The non-modifiable risk factors (e.g., younger age, being non-White, having more advanced stage disease) can inform current screening procedures. The potentially modifiable risk factors can be used to develop interventions to improve employment outcomes of breast cancer patients.
Appendix
Available only for authorised users
Literature
20.
21.
go back to reference Karnofsky D. Performance scale. New York: Plenum Press; 1977. Karnofsky D. Performance scale. New York: Plenum Press; 1977.
24.
go back to reference Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. JNCI. 2016;109(2):1–17. Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. JNCI. 2016;109(2):1–17.
25.
go back to reference Spielberger CG, Gorsuch RL, Suchene R, Vagg PR, Jacobs GA. Manual for the state-anxiety (form Y): self evaluation questionnaire. Palo Alto, CA: Consulting Psychologists Press; 1983. Spielberger CG, Gorsuch RL, Suchene R, Vagg PR, Jacobs GA. Manual for the state-anxiety (form Y): self evaluation questionnaire. Palo Alto, CA: Consulting Psychologists Press; 1983.
36.
go back to reference Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008;17(12):1189–95. https://doi.org/10.1002/pon.1342.CrossRefPubMed Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008;17(12):1189–95. https://​doi.​org/​10.​1002/​pon.​1342.CrossRefPubMed
40.
go back to reference Padilla GV, Ferrell B, Grant MM, Rhiner M. Defining the content domain of quality of life for Cancer-patients with pain. Cancer Nurs. 1990;13(2):108–15.CrossRef Padilla GV, Ferrell B, Grant MM, Rhiner M. Defining the content domain of quality of life for Cancer-patients with pain. Cancer Nurs. 1990;13(2):108–15.CrossRef
44.
go back to reference Muthen BO. Latent variable mixture modeling. In: new developments and techniques in structural equation modeling. Edn. Edited by Marcoulides GA, Schumacher RE. Mahwah, NJ: Lawrence Erlbaum Associates; 2001. Muthen BO. Latent variable mixture modeling. In: new developments and techniques in structural equation modeling. Edn. Edited by Marcoulides GA, Schumacher RE. Mahwah, NJ: Lawrence Erlbaum Associates; 2001.
45.
go back to reference Muthen LK, Muthen BO. Mplus User's guide (8th ed.), 8th edn. Los Angeles, CA: Muthen & Muthen; 1998-2020. Muthen LK, Muthen BO. Mplus User's guide (8th ed.), 8th edn. Los Angeles, CA: Muthen & Muthen; 1998-2020.
49.
go back to reference de Boer AG, Taskila TK, Tamminga SJ, Feuerstein M, Frings-Dresen MH, Verbeek JH. Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev. 2015;9:CD007569. de Boer AG, Taskila TK, Tamminga SJ, Feuerstein M, Frings-Dresen MH, Verbeek JH. Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev. 2015;9:CD007569.
50.
go back to reference Alfano CM, Kent EE, Padgett LS, Grimes M, de Moor JS. Making cancer rehabilitation services work for cancer patients: recommendations for research and practice to improve employment outcomes. PM R. 2017;9(9S2):S398–406.CrossRef Alfano CM, Kent EE, Padgett LS, Grimes M, de Moor JS. Making cancer rehabilitation services work for cancer patients: recommendations for research and practice to improve employment outcomes. PM R. 2017;9(9S2):S398–406.CrossRef
Metadata
Title
Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery
Authors
Raymond Javan Chan
Bruce Cooper
Louisa Gordon
Nicolas Hart
Chia Jie Tan
Bogda Koczwara
Kord M. Kober
Alexandre Chan
Yvette P. Conley
Steven M. Paul
Christine Miaskowski
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08583-0

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine